Peptide Comparisons
Structured side-by-side comparisons of peptides frequently researched for similar purposes. Each comparison covers mechanism differences, reported half-lives, dosing ranges, and practical distinctions to help orient research decisions.
All Comparisons
39 comparisons
01 BPC-157 vs TB-500
Tissue repair peptides: angiogenesis vs actin-mediated cell migration
Retatrutide vs Tirzepatide
Triple agonist (GLP-1/GIP/glucagon) vs dual agonist (GLP-1/GIP)
Retatrutide vs Semaglutide
Triple receptor agonist vs GLP-1 mono-agonist: breadth of metabolic action
Tirzepatide vs Semaglutide
Dual GLP-1/GIP agonist vs GLP-1 mono-agonist: approved compounds compared
Ipamorelin vs Sermorelin
Ghrelin receptor GHRP vs GHRH analogue: complementary GH axis pathways
Ipamorelin vs CJC-1295
GHRP + long-acting GHRH analogue: the most researched GH stack pairing
BPC-157 vs GHK-Cu
Systemic repair peptide vs copper-binding tripeptide for collagen and healing
Semax vs Selank
Stimulatory nootropic vs anxiolytic nootropic: Russian neuropeptides compared
PT-141 vs Melanotan II
MC4R-selective sexual function vs broad melanocortin agonism with tanning effect
Epitalon vs NAD+
Telomere/pineal longevity peptide vs mitochondrial NAD+ precursors
BPC-157 vs KPV
Systemic angiogenic repair vs targeted melanocortin gut anti-inflammatory
Ipamorelin vs GHRP-2
Selective GH-only GHRP vs potent GHRP with cortisol and prolactin elevation
CJC-1295 vs Sermorelin
Long-acting modified GHRH analogue vs short-acting physiological GHRH 1-29
Epitalon vs MOTS-c
Telomere/pineal longevity pathway vs mitochondrial metabolic regulation
Semaglutide vs Liraglutide
GLP-1 mono-agonists compared: weekly vs daily, 15% vs 8% weight loss, oral option
Tirzepatide vs Liraglutide
Dual GLP-1/GIP agonist vs GLP-1 mono-agonist: 20% vs 8% reported weight loss
Retatrutide vs CagriSema
Triple agonist (GLP-1/GIP/glucagon) vs GLP-1 + amylin: next-generation weight loss
Orforglipron vs Semaglutide
Oral non-peptide GLP-1 agonist vs injectable peptide: route and efficacy comparison
Ipamorelin vs Hexarelin
Selective GHRP vs most potent GHRP: selectivity vs peak GH amplitude tradeoff
Thymosin Alpha-1 vs LL-37
Adaptive T-cell immunity vs innate antimicrobial defence: complementary mechanisms
IGF-1 vs MK-677
Direct IGF-1 receptor agonist vs oral ghrelin mimetic raising GH and IGF-1 indirectly
Semax vs Cerebrolysin
Intranasal ACTH analogue vs IV peptide mixture: cognitive and neuroprotective research
Epitalon vs Pinealon
Khavinson bioregulators: telomerase/longevity tetrapeptide vs neural EDR tripeptide
Gonadorelin vs Triptorelin
GnRH agonists: pulsatile stimulatory vs continuous suppressive; TRT support vs oncology
Sermorelin vs HGH
GHRH analogue stimulating endogenous GH vs direct recombinant human growth hormone replacement
MK-677 vs HGH
Oral ghrelin mimetic raising GH indirectly vs injectable exogenous growth hormone
Ipamorelin vs HGH
Selective GHRP stimulating pituitary GH release vs direct HGH replacement
PT-141 vs Viagra (Sildenafil)
Central melanocortin CNS mechanism vs peripheral PDE5 inhibition: different pathways to sexual function
PT-141 vs Cialis (Tadalafil)
Central MC4R agonist vs long-acting PDE5 inhibitor: onset, duration, and mechanism compared
Semaglutide vs Metformin
GLP-1 receptor agonist vs biguanide: weight loss magnitude, mechanism, and cost compared
Tirzepatide vs Metformin
Dual GLP-1/GIP agonist vs first-line biguanide: efficacy and mechanism comparison
Gonadorelin vs Enclomiphene
GnRH agonist pituitary stimulation vs SERM hypothalamic feedback blockade in TRT protocols
Survodutide vs Semaglutide
GLP-1/glucagon dual agonist vs GLP-1 mono-agonist: adding thermogenesis to appetite suppression
BPC-157: Oral vs Injectable
Route comparison: systemic bioavailability and application differences for the same compound
GLP-1 vs GLP-2 vs GLP-3
Three proglucagon-derived peptides, three different receptors: metabolic/appetite vs intestinal repair vs emerging research
GHK-Cu vs AHK-Cu
Copper tripeptide comparison: broad skin repair vs targeted dermal papilla cell stimulation for hair
Tesamorelin vs CJC-1295
FDA-approved GHRH analogue for visceral adiposity vs long-acting GHRH analogue for general GH axis support
MOTS-c vs SS-31
Mitochondrially encoded metabolic signalling peptide vs synthetic cardiolipin-binding membrane protector
Semax vs Dihexa
Approved Russian neuropeptide with BDNF/NGF mechanism vs ultra-potent HGF/MET agonist with no human trial data